BioStem Technologies Reports 28% Revenue Decline and $8.97 Million Net Loss in Q2 2026

BioStem Technologies, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net revenue of $7.9 million for the three months ended June 30, 2026, a decrease of 28% compared to $11.0 million in the same period of 2025. For the first half of 2026, revenue fell to $14.0 million, down 48% from $26.9 million in the prior year. The decline in revenue was primarily attributed to reduced product pricing resulting from changes in Medicare reimbursement policies that took effect in January 2026, which decreased the revenue per square centimeter of products used in physician offices by up to 95%.

The company's financial performance was further impacted by a substantial increase in operating expenses. Total operating expenses for the second quarter of 2026 reached $13.2 million, up from $10.2 million in the same quarter of 2025. This increase was driven by a 317% rise in sales and marketing expenses, largely due to the acquisition of BioTissue's surgical and wound care product lines, which added to the company's sales force and marketing efforts. As a result, BioStem reported a net loss of $8.97 million for the second quarter of 2026, compared to a net income of $10,613 in the same quarter of the previous year.

In January 2026, BioStem expanded its product portfolio through the acquisition of assets from BioTissue Holdings, which included the Neox® and Clarix® product lines. This acquisition is expected to enhance the company's commercial capabilities and market presence. However, the company also faces a contingent payment obligation of up to $10 million related to the acquisition, which is due following the receipt of FDA clearance for the Catalyze product. The FDA granted this clearance on June 5, 2026, and the company has until September 15, 2026, to fulfill this payment, which will require additional financing.

Operationally, BioStem's customer base has shifted significantly. The company’s single distributor customer accounted for only 14% of revenue in the second quarter of 2026, down from 100% in the same period of 2025. This change reflects the company's efforts to diversify its revenue streams following the amendment of its distribution agreement with Venture Medical, which significantly reduced the per-unit consideration for products sold. The company is also exploring new arrangements to continue selling its AmnioWrap2 product, which was previously terminated due to unfavorable reimbursement rates.

Looking ahead, BioStem anticipates continued net losses and negative cash flows for at least the next twelve months as it navigates the impacts of reduced product pricing and its obligations related to the BioTissue acquisition. The company plans to finance its operations through existing cash reserves, anticipated revenue from product sales, and potential equity or debt financing. However, there is substantial doubt about its ability to continue as a going concern if it cannot secure the necessary funding.